OpenAI has introduced GPT-Rosalind, a specialized AI model designed for biology, medical research, and drug discovery. Unlike general-purpose language models, GPT-Rosalind reads scientific publications, formulates hypotheses, and plans experiments on complex biological systems.

The model integrates with over 50 scientific tools and databases, working directly with genes, proteins, and molecular pathways to fit into real research pipelines. It achieved a score of 0.751 on BixBench, outperforming previous solutions in 6 out of 11 scientific tasks and surpassing the 95th percentile of human experts in RNA structure prediction.

Major biotech companies are already testing GPT-Rosalind in drug discovery pipelines, signaling a potential shift where specialized scientific AI agents become core units of R&D.

Read more on OpenAI’s official announcement